EGFR and cancer: The activity and selectivity of BA against cancer cells expressing EGFR were assessed in a panel of cell lines, including NSCLC cell lines harboring either the EGFRL858/T790M double mutation (H1975 cells) or EGFRexon19del (PC-9 and H827 cells) and two cell lines expressing wt-EGFR (A549 and H1299).